Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
Translational Oncology, 2023 Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed ...
Lijuan Bai +15 more
doaj +2 more sources
Repurposing of Bromocriptine for Cancer Therapy [PDF]
Frontiers in Pharmacology, 2018 Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo +3 more
doaj +2 more sources
Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases [PDF]
American Journal of Perinatology Reports, 2018 Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.
Rebecca Simon +2 more
doaj +2 more sources
Bromocriptine and insulin sensitivity in lean and obese subjects
Endocrine Connections, 2016 Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler +6 more
doaj +2 more sources
Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis
Cancer Cell International, 2007 Background Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of ...
Huang Mu-Chiou +7 more
doaj +2 more sources
Impact of bromocriptine withdrawal timing on pregnancy outcomes in patients with pituitary prolactin-secreting microadenomas: a real-world retrospective study of 188 pregnancies in China [PDF]
Frontiers in PharmacologyBackgroundThis study aims to evaluate the influence of the timing for bromocriptine withdrawal in pregnant women with pituitary prolactin-secreting microadenomas.MethodsIn this retrospective study,188 pregnant women diagnosed with pituitary prolactin ...
Jiao Lan +14 more
doaj +2 more sources
Bromocriptine in peripartum cardiomyopathy: A meta‐analysis with trial sequential analysis [PDF]
ESC Heart FailureBromocriptine has been proposed as a disease‐modifying therapy for peripartum cardiomyopathy (PPCM). The long‐term outcomes of bromocriptine use remain uncertain.
Umar G. Adamu +3 more
doaj +2 more sources
Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors [PDF]
Journal of NanobiotechnologyIntranasal drug delivery via nanocarriers has long been a research focus for enhancing drug concentration in the brain. However, the strategy of exploiting blood–brain barrier (BBB) alterations in atherosclerotic mouse models to enhance nanoparticle ...
Zhe Zhang +12 more
doaj +2 more sources
PLoS ONEBromocriptine, generally regarded as a dopamine D2 receptor agonist, has been used to treat patients with type 2 diabetes in the USA; however, its mechanisms of action including the receptors that mediate its anti-diabetic effects remain unclear ...
Hiroshi Tsuneki +11 more
doaj +2 more sources
Management of posttraumatic refractory paroxysmal sympathetic hyperactivity with bromocriptine: a case report [PDF]
Journal of Trauma and InjuryThis case report describes a unique instance of refractory paroxysmal sympathetic hyperactivity (PSH) in a 19-year-old woman following a traumatic brain injury sustained in a motorcycle accident.
Min-Seok Woo +3 more
doaj +2 more sources